Subscribe
unusedbrandon-bourdages-shutterstock-com-us-supreme-court--1
Brandon Bourdages / Shutterstock.com
5 December 2016Americas

Life Technologies v Promega to be heard at US Supreme Court

Oral arguments in Life Technologies v Promega are due to take place tomorrow in the US Supreme Court to determine whether the US Court of Appeals for the Federal Circuit correctly defined “substantial portion”.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
SCOTUS reverses Federal Circuit in Life Technologies v Promega
22 February 2017   The US Supreme Court today ruled that supplying a single component of a multi-component invention for manufacture abroad does not constitute patent infringement.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Americas
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Americas
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

More on this story

Americas
SCOTUS reverses Federal Circuit in Life Technologies v Promega
22 February 2017   The US Supreme Court today ruled that supplying a single component of a multi-component invention for manufacture abroad does not constitute patent infringement.

More on this story

Americas
SCOTUS reverses Federal Circuit in Life Technologies v Promega
22 February 2017   The US Supreme Court today ruled that supplying a single component of a multi-component invention for manufacture abroad does not constitute patent infringement.

More features

Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler
WilmerHale gains partner with ‘deep expertise’
Bayer, Orion take on Indian generic over $117bn drug
‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court